CP3 Study

A doctor holds his hands in a heart shape. The CP3 study logo is overlaid.

Increasing the lifespan and health of individuals living with psoriatic disease through personalized cardiovascular disease prevention care.

Psoriasis increases your risk of developing heart disease.

Psoriatic disease is associated with inflammation throughout the body, increasing the risk of high cholesterol, high blood pressure, and diabetes, among other comorbidities.

Did You Know?

One of the goals identified in the National Psoriasis Foundation's 2020 – 2024 Strategic Plan is to increase the lifespan and health of individuals living with psoriatic disease. Research has shown that people living with psoriatic disease have a reduced life expectancy, which is due to an increased risk of cardiovascular disease (CVD), including heart attack and stroke. [1] Individuals living with psoriatic disease are more likely to have underdiagnosed and undertreated CVD risk factors, such as high blood pressure and high cholesterol. [2]

Funded through NPF's Psoriasis Prevention Initiative, the CP3 study is evaluating the use of an innovative care coordination model in lowering cardiovascular risk in patients with psoriatic disease. Care coordinators meet with enrolled patients living with psoriasis who have an elevated risk of CVD and guide them through their CVD risk calculations, review their risk profile, help develop a diet, exercise, and medication plan, and connect them with a primary care provider.

Study Team

CP3 consists of a multi-disciplinary and institutional team of investigators with sites throughout the United States.

Meet the team

Join CP3

Interested in participating? Find a study site near you or become a study site.

Learn more


Frequently asked questions for patients and health care providers.

Find answers


Get in touch with the CP3 Study team at cp3study@pennmedicine.upenn.edu.


1.       Mehta N, Azfar R, Shin D, et al. Patients with Severe Psoriasis are at Increased Risk of Cardiovascular Mortality: Cohort Study Using the General Practice Research Database. Eur Heart J. April 31, 2010. doi: 10.1093/eurheartj/ehp567

2.       Kimball A, Szapary P, Mrowietz U, et al. Underdiagnosis and Undertreatment of Cardiovascular Risk Factors in Patients with Moderate to Severe Psoriasis. J Am Acad Dermatol. July 2012. doi: 10.1016/j.jaad.2011.06.035

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2023 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.